Related Experiment Video
Updated: Feb 15, 2026

Single-Molecule Imaging of EWS-FLI1 Condensates Assembling on DNA
Published on: September 8, 2021
EWS/FLI Confers Tumor Cell Synthetic Lethality to CDK12 Inhibition in Ewing Sarcoma
Amanda Balboni Iniguez1, Björn Stolte2, Emily Jue Wang1
1Department of Pediatric Oncology, Dana-Farber Cancer Institute and Boston Children's Hospital, Harvard Medical School, 450 Brookline Avenue, Boston, MA 02215, USA; The Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA.
Abstract:
Many cancer types are driven by oncogenic transcription factors that have been difficult to drug. Transcriptional inhibitors, however, may offer inroads into targeting these cancers. Through chemical genomics screening, we identified that Ewing sarcoma is a disease with preferential sensitivity to THZ1, a covalent small-molecule CDK7/12/13 inhibitor. The selective CDK12/13 inhibitor, THZ531, impairs DNA damage repair in an EWS/FLI-dependent manner, supporting a synthetic lethal relationship between response to THZ1/THZ531 and EWS/FLI expression. The combination of these molecules with PARP inhibitors showed striking synergy in cell viability and DNA damage assays in vitro and in multiple models of Ewing sarcoma, including a PDX, in vivo without hematopoietic toxicity.
Insights
Ewing sarcoma shows sensitivity to CDK inhibitors THZ1 and THZ531, which target oncogenic transcription factors. Combining these with PARP inhibitors demonstrates significant synergy in preclinical models, offering a potential new treatment strategy.
Area of Science:
- Oncology
- Molecular Biology
- Drug Discovery
Background:
- Many cancers are driven by transcription factors that are challenging to target with drugs.
- Transcriptional inhibitors represent a promising therapeutic strategy for these cancers.
Purpose of the Study:
- To identify novel therapeutic vulnerabilities in Ewing sarcoma.
- To investigate the efficacy of CDK7/12/13 and CDK12/13 inhibitors in Ewing sarcoma models.
Main Methods:
- Chemical genomics screening to identify drug sensitivities.
- In vitro and in vivo studies using Ewing sarcoma cell lines and patient-derived xenografts (PDX).
- Assays for cell viability, DNA damage, and hematopoietic toxicity.
Main Results:
- Ewing sarcoma exhibits preferential sensitivity to THZ1, a CDK7/12/13 inhibitor.
- THZ531, a selective CDK12/13 inhibitor, impairs DNA damage repair in an EWS/FLI-dependent manner.
- Combination therapy with THZ1/THZ531 and PARP inhibitors showed significant synergy in preclinical models, including PDX models, without hematopoietic toxicity.
Conclusions:
- A synthetic lethal relationship exists between EWS/FLI expression and response to THZ1/THZ531.
- The combination of CDK inhibitors and PARP inhibitors is a promising therapeutic strategy for Ewing sarcoma.
- This combination demonstrates efficacy in vivo without significant side effects.
Related Concept Videos
Lethal Alleles
Lucien Cuénot discovered lethal alleles in 1905 while studying the inheritance of coat color in mice. The agouti gene is responsible for the color of the coat in mice. This gene codes for an agouti-signaling protein, which is responsible for melanin distribution in mammals. The wild-type allele gives rise to gray-brown coat color in mice, while the mutant allele gives rise to yellow coat color. In addition to coat color, the agouti gene is associated with the yellow...
Feedback Inhibition
Synthetic Biology
Golden rice
Golden rice is a genetically modified...
Rous Sarcoma Virus (RSV) and Cancer
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
Synthetic Disvision of Polynomials
Enzyme Inhibition

